Skip to content

US · LYEL · BIOTECHNOLOGY

Lyell Immunopharma, Inc. (LYEL) intrinsic value and stock valuation

$13.80as of 2026-11-21 · Mkt cap 329.58M

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lyell Immunopharma, Inc. DCF and intrinsic value

InvestorsCraft values LYEL with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from LYEL’s statements →

Lyell Immunopharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 lyell.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$40K-65.1% 5y CAGRd
20192025
Net income
-$-274.45M
20192025
Free cash flow
-$-150.8M
20192025
Total equity
$248.2M-19.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$40K$60K$130K$84.7M$10.7M
Operating income-$-203.77M-$-358.75M-$-247.01M-$-187.06M-$-214.78M
Net income-$-274.45M-$-342.99M-$-234.63M-$-183.12M-$-250.22M
EPSd-$-16.06M-$-26.24M-$-18.7M-$-14.83M-$-20.61M
Operating cash flow-$-150.02M-$-162.39M-$-163.69M-$-169.56M-$-126.25M
Capital expenditure-$-780K-$-460K-$-2.69M-$-24.28M-$-65.5M
Free cash flow-$-150.8M-$-162.86M-$-166.38M-$-193.83M-$-191.75M
Total assets$340.1M$490.9M$750M$937.6M$1.13B
Total debt$51M$59M$63.2M$67.7M$67.8M
Net debt-$-9.19M-$-46.63M-$-82.48M-$-55.85M-$-226.01M
Total equity$248.2M$382.8M$655M$833.3M$929.8M
Cash and short-term investments$247.2M$370.5M$546.2M$640.2M$614.8M
Income statement
20252024202320222021
Revenue$40K$60K$130K$84.7M$10.7M
Cost of revenue$11.5M$0.00$0.00$0.00$0.00
Gross profit-$-11.5M$60K$130K$84.7M$10.7M
Research and development expenses$158.7M$171.6M$182.9M$159.2M$138.7M
Selling, general and administrative expenses$45.1M$52M$67M$117.3M$89.1M
Other expenses-$-11.54M$135.2M-$-2.79M-$-4.75M-$-2.32M
Operating expenses$192.3M$358.8M$247.1M$271.7M$225.4M
Cost and expenses$203.8M$358.8M$247.1M$271.7M$225.4M
Interest income$13.1M$24.1M$23.5M$7.05M$1.17M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$11.5M$19.6M$20.3M$18M$13.6M
Ebitda-$-262.91M-$-200.64M-$-214.38M-$-165.1M-$-236.59M
Operating income-$-203.77M-$-358.75M-$-247.01M-$-187.06M-$-214.78M
Total other income/expenses, net-$-70.67M$15.8M$12.4M$3.94M-$-35.44M
Income before tax-$-274.45M-$-342.99M-$-234.63M-$-183.12M-$-250.22M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-274.45M-$-342.99M-$-234.63M-$-183.12M-$-250.22M
Weighted average shares outstanding$17.1M$13.1M$12.6M$12.4M$12.1M
Weighted average diluted shares outstanding$17.1M$13.1M$12.6M$12.4M$12.1M
Balance sheet
20252024202320222021
Cash and short-term investments$247.2M$370.5M$546.2M$640.2M$614.8M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$260.9M$379.6M$554.7M$651.3M$626.3M
Property, plant and equipment, net$53.6M$72.9M$142.3M$166.3M$166.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$19M$32M$48.5M$115M$330.5M
Total non-current assets$79.1M$111.3M$195.3M$286.3M$501.1M
Total assets$340.1M$490.9M$750M$937.6M$1.13B
Accounts payable$2.89M$5.37M$4.82M$3.92M$3.21M
Short-term debt$9.07M$7.97M$6.27M$4.53M$1.17M
Deferred revenue$2.54M$0.00$0.00$0.00$4.99M
Total current liabilities$49.4M$53.8M$34.5M$37M$46.7M
Long-term debt$41.9M$51M$56.9M$63.2M$66.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$79.7M
Total non-current liabilities$42.4M$54.3M$60.6M$67.3M$150.9M
Capital lease obligations$51M$59M$63.2M$67.7M$67.8M
Total liabilities$91.9M$108M$95.1M$104.3M$197.6M
Common stock$0.00$30K$30K$30K$20K
Retained earnings-$-1.62B-$-1.35B-$-1B-$-767.48M-$-584.36M
Accumulated other comprehensive income (loss)$240K$290K-$-90K-$-7.6M-$-1.62M
Total equity$248.2M$382.8M$655M$833.3M$929.8M
Total investments$206M$296.9M$449.1M$631.6M$651.5M
Total debt$51M$59M$63.2M$67.7M$67.8M
Net debt-$-9.19M-$-46.63M-$-82.48M-$-55.85M-$-226.01M
Cash flow statement
20252024202320222021
Net income-$-274.45M-$-342.99M-$-234.63M-$-183.12M-$-250.22M
Depreciation and amortization$11.5M$19.6M$20.3M$16.5M$13.6M
Stock-based compensation$41.8M$33.1M$47.1M$0.00$62.2M
Change in working capital-$-9.89M-$-3.12M$3.42M-$-82.02M$4.01M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.34M-$-3.23M$1.46M$670K$90K
Net cash provided by operating activities-$-150.02M-$-162.39M-$-163.69M-$-169.56M-$-126.25M
Investments in property, plant and equipment-$-780K-$-460K-$-2.69M-$-24.28M-$-65.5M
Acquisitions, net-$-41.2M-$-31.35M$0.00$0.00$673.5M
Net cash used for investing activities$54.1M$122.4M$184.1M-$-11.54M-$-121.57M
Common stock issued$50.4M$1.4M$2.2M$11.1M$391.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$50.4M$1.33M$1.74M$10.6M$401.2M
Net change in cash-$-45.52M-$-38.64M$22.1M-$-170.27M$153.4M
Cash at end of period$61.8M$107.3M$145.7M$123.6M$294.3M
Operating cash flow-$-150.02M-$-162.39M-$-163.69M-$-169.56M-$-126.25M
Capital expenditure-$-780K-$-460K-$-2.69M-$-24.28M-$-65.5M
Free cash flow-$-150.8M-$-162.86M-$-166.38M-$-193.83M-$-191.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lyell Immunopharma, Inc.

        Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

        CEO
        Lynn Seely
        Employees
        161
        Beta
        -0.06

        Explore

        Frequently asked questions

        What is the intrinsic value of Lyell Immunopharma, Inc. (LYEL)?

        Lyell Immunopharma, Inc. (LYEL) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LYEL undervalued?

        LYEL trades at a price of $13.80 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.